A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

Inclusion Criteria:

1. Diagnosed ≥ 12 weeks before the screening visit and qualify as having SLE according to the SLE International Collaborating Clinics (SLICC) Classification Criteria at the screening visit
2. Test positive, as determined by the central laboratory, for at least one of the following lupus related autoantibodies at the time of screening: antinuclear antibody ≥ 1:80, anti-double-stranded deoxyribonucleic acid (dsDNA) antibody, or anti-Smith antibody.
3. Have a total Hybrid Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score ≥ 6 points and clinical Hybrid SLEDAI score ≥ 4 points with joint involvement and/or rash

Exclusion Criteria:

1. Active severe lupus nephritis (LN) as assessed by the investigator
2. Active or unstable neuropsychiatric lupus manifestations defined by the Hybrid SLEDAI
3. Diagnosis of Mixed Connective Tissue Disease for which the predominant diagnosis is not SLE
4. Antiphospholipid Syndrome

Other protocol-defined inclusion/exclusion criteria apply